The immunoglobulin molecule contains structural features that make it a powerful tool for
cancer therapy (eg, an extremely high specificity and binding affinity for the target molecule
that results in low toxicity). Several approaches have been used: monoclonal antibodies
targeting a ligand (eg, bevacizumab, anti-vascular endothelial growth factor), monoclonal
antibodies targeting a receptor (eg, cetuximab, anti-epidermal growth factor receptor),
vaccines targeting a ligand (eg, G17DT, anti-gastrin), or a cell surface antigen (eg …